University of Nottingham – Confidence in Concept 2019
Lead Research Organisation:
University of Nottingham
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding.
Organisations
People |
ORCID iD |
Publications
Latif A
(2022)
Microparticles Decorated with Cell-Instructive Surface Chemistries Actively Promote Wound Healing.
in Advanced materials (Deerfield Beach, Fla.)
| Description | Designing bio-instructive materials for translation ready medical devices |
| Amount | £4,074,945 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2023 |
| End | 01/2027 |
| Description | ICURe Award to Prof. Chappell |
| Amount | £31,337 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Impact Accelerator Award to Prof. Shaw / Dr Clifford |
| Amount | £19,000 (GBP) |
| Organisation | University of Nottingham |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 07/2022 |
| End | 07/2023 |
| Company Name | ISOMAB LTD |
| Description | IsomAb is developing isoform specific, humanised IgG1 based antibodies and it has identified, using a combined bioinformatics/knowledge-based platform approach, its first antibody against Vascular Endothelial Growth Factor A (VEGF-A). Our strategy utilises an antibody to specifically inhibit the VEGF-A165b isoforms; based on 20 years of research, the evidence shows this isoform is key to preventing collateral vessel formation in ischemic diseases. |
| Year Established | 2022 |
| Impact | IsomAb is a pre-clinical stage company with Proof-of-Concept data, in two animal models, and an ambitious plan to take its first product into the clinic by 2026. |
| Website | https://www.isomab.bio/ |